<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9280">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762268</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000276</org_study_id>
    <nct_id>NCT00762268</nct_id>
  </id_info>
  <brief_title>A Trial of SAMe for Treatment-Resistant Bipolar Depression</brief_title>
  <official_title>Intermittent-Dose Oral SAMe (S-adenosyl-L-methionine) in Persistent and Treatment-Refractory Bipolar Depression: A Double-Blind Pilot Trial With an Optional Open-label Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties.
      SAMe's mechanism of action remains unclear, but it appears to be distinct from that of
      conventional antidepressants. The purpose of this study is to examine the effect of these
      properties on the mood of bipolar subjects with persistent major depression that has been
      unresponsive to standard pharmacotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression in bipolar disorder is a significant source of disease-related debility; with
      bipolar individuals typically spending three fold as much time depressed as manic or
      hypomanic. Clinicians treating bipolar disorder often struggle to provide relief from
      depressive symptoms that are more often treatment resistant than in unipolar depression. To
      complicate matters further, the risk/benefit ratio of currently available antidepressants is
      a source of debate within the field of psychiatry.

      S-adenosyl-L-methionine (SAMe) is a dietary supplement with well-established antidepressant
      properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from
      that of conventional antidepressants. The purpose of this study is to examine the effect of
      these properties on the mood of bipolar subjects with persistent major depression that has
      been unresponsive to standard pharmacotherapy.

      An unusual aspect of the current study design is the schedule of SAMe dosing. SAMe tablets
      will be administered intermittently and in steadily increasing dosages. The purpose of this
      gradual and intermittent dosage titration is to lessen the risk of antidepressant-induced
      mania by seeking the minimum effective oral dose of SAMe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MADRS</measure>
    <time_frame>At each weekly visit for 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of current mania symptoms using Mania Acute Change Scale (MACS). All 20 questions on the scale have a 0 (absent)-4(most severe) range for describing mania symptoms. The mean MACS score totals were reported, with the total ranging from 0-80. A higher total score indicates a greater number of symptoms and higher symptom intensity, while a smaller score indicates a lesser number of symptoms and lower intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAM-D</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>YMRS</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>SAMe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMe</intervention_name>
    <description>SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.</description>
    <arm_group_label>SAMe</arm_group_label>
    <other_name>S-adenosyl-L-methionine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bipolar disorder

          -  depressed for 3-12 months

          -  mood unresponsive to at least 2 treatments

          -  currently on mood stabilizer at therapeutic doses

        Exclusion Criteria:

          -  history of mania while on adequate mood stabilizer

          -  rapid cycling bipolar disorder

          -  previous use of SAMe during current episode

          -  unstable medical illness including parkinson's disease

          -  methotrexate use

          -  pregnancy

          -  substance abuse/dependence
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth L Murphy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mclean.harvard.edu</url>
    <description>link to hospital web site with clinical trials information</description>
  </link>
  <results_reference>
    <citation>Murphy BL, Babb SM, Ravichandran C, Cohen BM. Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial. J Clin Psychopharmacol. 2014 Jun;34(3):413-6. doi: 10.1097/JCP.0000000000000064.</citation>
    <PMID>24699040</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 25, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2008</firstreceived_date>
  <firstreceived_results_date>June 17, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Beth L. Murphy MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SAMe</keyword>
  <keyword>alternative treatments</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>depression</keyword>
  <keyword>bipolar depression</keyword>
  <keyword>treatment-resistant depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SAMe</title>
          <description>SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Individuals entering the treatment phase of the study.</population>
      <group_list>
        <group group_id="B1">
          <title>SAMe</title>
          <description>SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MADRS</title>
        <description>Assessment of current mania symptoms using Mania Acute Change Scale (MACS). All 20 questions on the scale have a 0 (absent)-4(most severe) range for describing mania symptoms. The mean MACS score totals were reported, with the total ranging from 0-80. A higher total score indicates a greater number of symptoms and higher symptom intensity, while a smaller score indicates a lesser number of symptoms and lower intensity.</description>
        <time_frame>At each weekly visit for 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>SAMe</title>
            <description>SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>MADRS</title>
            <description>Assessment of current mania symptoms using Mania Acute Change Scale (MACS). All 20 questions on the scale have a 0 (absent)-4(most severe) range for describing mania symptoms. The mean MACS score totals were reported, with the total ranging from 0-80. A higher total score indicates a greater number of symptoms and higher symptom intensity, while a smaller score indicates a lesser number of symptoms and lower intensity.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.4" lower_limit="17" upper_limit="39"/>
                  <measurement group_id="O2" value="28.3" lower_limit="18" upper_limit="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.7" lower_limit="10" upper_limit="37"/>
                  <measurement group_id="O2" value="24.2" lower_limit="11" upper_limit="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.3" lower_limit="16" upper_limit="46"/>
                  <measurement group_id="O2" value="23.0" lower_limit="8" upper_limit="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.7" lower_limit="8" upper_limit="35"/>
                  <measurement group_id="O2" value="18.5" lower_limit="8" upper_limit="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.1" lower_limit="8" upper_limit="31"/>
                  <measurement group_id="O2" value="18.1" lower_limit="8" upper_limit="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>1.0</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAM-D</title>
        <time_frame>6-weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>YMRS</title>
        <time_frame>6-weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SAMe</title>
          <description>SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day &quot;rest-period&quot;, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beth Murphy MD</name_or_title>
      <organization>McLean Hospital</organization>
      <phone>617-855-2297</phone>
      <email>BMurphy5@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
